CD8A and non-small cell lung carcinoma: performed sequencing of complementarity-determining region 3 of TCRβ chains isolated from PD-1+ CD8+ T cells to evaluate its value as a biomarker to predict the response to anti-PD-1/PD-L1 therapy in NSCLC patients (108).